The firm is leveraging its expertise in the immuno-oncology space to expedite development of newer agents like the bispecific ...

Trump demanded that pharmaceutical companies lower their drug prices. But it's unclear how the government may enforce the ...

Bristol Myers Squibb & Co (NYSE:BMY) reported second-quarter 2025 revenues of $12.27 billion, beating the consensus of $11.31 ...

President Trump on Thursday sent letters to 17 of the world’s largest drug companies, telling them to take more steps to ...

Merck will reduce its workforce by approximately 6,000 employees in “some areas of our global workforce,” the New Jersey ...

Trump posted individual letters he sent 17 drugmakers, including Eli Lilly, GSK, Pfizer, Regeneron, Merck, Pfizer and Novo ...

Trump specifically asked that those companies offer the MFN price to Medicaid recipients and to promise that they wouldn't ...

Trump sent a letter to 17 drug companies demanding a commitment to lower prices in the next 60 days through a series of initiatives.

Bristol Myers Squibb reported unexpectedly strong second-quarter results, driven by legacy products like Eliquis, despite ...

Cobenfy is one of the key products Bristol is counting on to take up the slack as patents on three of its top-selling drugs ...

Bristol Myers Squibb tested Cobenfy as an adjunctive treatment with atypical antipsychotics for schizophrenia in the Phase ...

Live Updates Live Coverage Updates appear automatically as they are published. MassterCard Charges Ahead 10:00 am In further ...